Bioengineer.org’s Post

How to ensure a cancer treatment works as well as it can, for as long as it can? …By targeting treatment-resistant mutations using "Off Target" targeted therapies! Watch this video to learn👇 ✅ What treatment-resistant genes are ✅ What a genetic mutation is ✅ How many mutations each gene can actually have ✅ Why standard genetic testing just doesn’t cut it ✅ The foundation of Precision Oncology - identifying targetable driving mutations ✅ What happens if a patient has a mutation with no therapeutic strategies ✅ New insights on this topic from computational simulations ✅ Exploring a case study with the EGFR mutation ✅ An inspiring patient story using this exact strategy – with great success! ✅ Next steps a patient can take to determine their best treatment strategy and how to access it asap In this video, Precision Oncology specialist, Alex Rolland, discusses how to target treatment-resistant mutations using “off target” targeted drugs. Many patients on targeted therapies can develop treatment resistant mutations or may have treatment-resistant mutations at the start of treatment... Alex explains how we can use targeted drugs that would normally only be used to target other genes by looking at the mechanisms unique to each mutation and drug and matching them – in other words, by matching the drug mechanism to the mutation mechanism. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that all cancer patients, their loved ones, and their doctors need to know about using “off target” targeted therapies to target treatment-resistant mutations. Click to watch 👉 https://buff.ly/3wQ08ew 👀 #HopeIsHere #PrecisionCancerMedicine

How to ensure a cancer treatment works as well as it can, for as long as it can? …By targeting treatment-resistant mutations using "Off Target" targeted therapies! Watch this video to learn👇 ✅ What treatment-resistant genes are ✅ What a genetic mutation is ✅ How many mutations each gene can actually have ✅ Why standard genetic testing just doesn’t cut it ✅ The foundation of Precision Oncology - identifying targetable driving mutations ✅ What happens if a patient has a mutation with no therapeutic strategies ✅ New insights on this topic from computational simulations ✅ Exploring a case study with the EGFR mutation ✅ An inspiring patient story using this exact strategy – with great success! ✅ Next steps a patient can take to determine their best treatment strategy and how to access it asap In this video, Precision Oncology specialist, Alex Rolland, discusses how to target treatment-resistant mutations using “off target” targeted drugs. Many patients on targeted therapies can develop treatment resistant mutations or may have treatment-resistant mutations at the start of treatment... Alex explains how we can use targeted drugs that would normally only be used to target other genes by looking at the mechanisms unique to each mutation and drug and matching them – in other words, by matching the drug mechanism to the mutation mechanism. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that all cancer patients, their loved ones, and their doctors need to know about using “off target” targeted therapies to target treatment-resistant mutations. Click to watch 👉 https://buff.ly/3wQ08ew 👀 #HopeIsHere #PrecisionCancerMedicine

How to ensure a cancer treatment works as well as it can, for as long as it can? …By targeting treatment-resistant mutations using "Off Target" targeted therapies! Watch this video to learn👇 ✅ What treatment-resistant genes are ✅ What a genetic mutation is ✅ How many mutations each gene can actually have ✅ Why standard genetic testing just doesn’t cut it ✅ The foundation of Precision Oncology - identifying targetable driving mutations ✅ What happens if a patient has a mutation with no therapeutic strategies ✅ New insights on this topic from computational simulations ✅ Exploring a case study with the EGFR mutation ✅ An inspiring patient story using this exact strategy – with great success! ✅ Next steps a patient can take to determine their best treatment strategy and how to access it asap In this video, Precision Oncology specialist, Alex Rolland, discusses how to target treatment-resistant mutations using “off target” targeted drugs. Many patients on targeted therapies can develop treatment resistant mutations or may have treatment-resistant mutations at the start of treatment... Alex explains how we can use targeted drugs that would normally only be used to target other genes by looking at the mechanisms unique to each mutation and drug and matching them – in other words, by matching the drug mechanism to the mutation mechanism. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that all cancer patients, their loved ones, and their doctors need to know about using “off target” targeted therapies to target treatment-resistant mutations. Click to watch 👉 https://buff.ly/3wQ08ew 👀 #HopeIsHere #PrecisionCancerMedicine

How to ensure a cancer treatment works as well as it can, for as long as it can? …By targeting treatment-resistant mutations using "Off Target" targeted therapies! Watch this video to learn👇 ✅ What treatment-resistant genes are ✅ What a genetic mutation is ✅ How many mutations each gene can actually have ✅ Why standard genetic testing just doesn’t cut it ✅ The foundation of Precision Oncology - identifying targetable driving mutations ✅ What happens if a patient has a mutation with no therapeutic strategies ✅ New insights on this topic from computational simulations ✅ Exploring a case study with the EGFR mutation ✅ An inspiring patient story using this exact strategy – with great success! ✅ Next steps a patient can take to determine their best treatment strategy and how to access it asap In this video, Precision Oncology specialist, Alex Rolland, discusses how to target treatment-resistant mutations using “off target” targeted drugs. Many patients on targeted therapies can develop treatment resistant mutations or may have treatment-resistant mutations at the start of treatment... Alex explains how we can use targeted drugs that would normally only be used to target other genes by looking at the mechanisms unique to each mutation and drug and matching them – in other words, by matching the drug mechanism to the mutation mechanism. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that all cancer patients, their loved ones, and their doctors need to know about using “off target” targeted therapies to target treatment-resistant mutations. Click to watch 👉 https://buff.ly/3wQ08ew 👀 #HopeIsHere #PrecisionCancerMedicine

How to ensure a cancer treatment works as well as it can, for as long as it can? …By targeting treatment-resistant mutations using "Off Target" targeted therapies! Watch this video to learn👇 ✅ What treatment-resistant genes are ✅ What a genetic mutation is ✅ How many mutations each gene can actually have ✅ Why standard genetic testing just doesn’t cut it ✅ The foundation of Precision Oncology - identifying targetable driving mutations ✅ What happens if a patient has a mutation with no therapeutic strategies ✅ New insights on this topic from computational simulations ✅ Exploring a case study with the EGFR mutation ✅ An inspiring patient story using this exact strategy – with great success! ✅ Next steps a patient can take to determine their best treatment strategy and how to access it asap In this video, Precision Oncology specialist, Alex Rolland, discusses how to target treatment-resistant mutations using “off target” targeted drugs. Many patients on targeted therapies can develop treatment resistant mutations or may have treatment-resistant mutations at the start of treatment... Alex explains how we can use targeted drugs that would normally only be used to target other genes by looking at the mechanisms unique to each mutation and drug and matching them – in other words, by matching the drug mechanism to the mutation mechanism. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that all cancer patients, their loved ones, and their doctors need to know about using “off target” targeted therapies to target treatment-resistant mutations. Click to watch 👉 https://buff.ly/3wQ08ew 👀 #HopeIsHere #PrecisionCancerMedicine

How to ensure a cancer treatment works as well as it can, for as long as it can? …By targeting treatment-resistant mutations using "Off Target" targeted therapies! Watch this video to learn👇 ✅ What treatment-resistant genes are ✅ What a genetic mutation is ✅ How many mutations each gene can actually have ✅ Why standard genetic testing just doesn’t cut it ✅ The foundation of Precision Oncology - identifying targetable driving mutations ✅ What happens if a patient has a mutation with no therapeutic strategies ✅ New insights on this topic from computational simulations ✅ Exploring a case study with the EGFR mutation ✅ An inspiring patient story using this exact strategy – with great success! ✅ Next steps a patient can take to determine their best treatment strategy and how to access it asap In this video, Precision Oncology specialist, Alex Rolland, discusses how to target treatment-resistant mutations using “off target” targeted drugs. Many patients on targeted therapies can develop treatment resistant mutations or may have treatment-resistant mutations at the start of treatment... Alex explains how we can use targeted drugs that would normally only be used to target other genes by looking at the mechanisms unique to each mutation and drug and matching them – in other words, by matching the drug mechanism to the mutation mechanism. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that all cancer patients, their loved ones, and their doctors need to know about using “off target” targeted therapies to target treatment-resistant mutations. Click to watch 👉 https://lnkd.in/g3TwD8FX 👀 #HopeIsHere #PrecisionCancerMedicine    

How to ensure a cancer treatment works as well as it can, for as long as it can? …By targeting treatment-resistant mutations using "Off Target" targeted therapies! Watch this video to learn👇 ✅ What treatment-resistant genes are ✅ What a genetic mutation is ✅ How many mutations each gene can actually have ✅ Why standard genetic testing just doesn’t cut it ✅ The foundation of Precision Oncology - identifying targetable driving mutations ✅ What happens if a patient has a mutation with no therapeutic strategies ✅ New insights on this topic from computational simulations ✅ Exploring a case study with the EGFR mutation ✅ An inspiring patient story using this exact strategy – with great success! ✅ Next steps a patient can take to determine their best treatment strategy and how to access it asap In this video, Precision Oncology specialist, Alex Rolland, discusses how to target treatment-resistant mutations using “off target” targeted drugs. Many patients on targeted therapies can develop treatment resistant mutations or may have treatment-resistant mutations at the start of treatment... Alex explains how we can use targeted drugs that would normally only be used to target other genes by looking at the mechanisms unique to each mutation and drug and matching them – in other words, by matching the drug mechanism to the mutation mechanism. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that all cancer patients, their loved ones, and their doctors need to know about using “off target” targeted therapies to target treatment-resistant mutations. Click to watch 👉 https://buff.ly/3wQ08ew 👀 #HopeIsHere #PrecisionCancerMedicine

The new insights shift the focus from targeting protein aggregates to managing the stress response mechanism and introduce the potential for new treatment strategies.

Interesting concept: combining an IL-15 moiety with CD19 or CD20 antibody-mediated targeting activates NK cells against leukemic cells 😉😉😉 https://lnkd.in/gZsBJETP

Meet me at the poster board no. 22 in 15 min at the SNMMI Meeting! We are sharing unpublished data on 225Ac-labelled SSO110 - our proprietary antagonistic SSTR2 targeting peptide - that will enter clinical phase in Q1/2025! The data show that we have significantly better anti-tumor efficacy than 225Ac-DOTATATE.